

## **ITGAV Polyclonal Antibody**

Catalog Number: E92091
Amount: 100ul

**Background:** Integrins are  $\alpha/\beta$  heterodimeric cell surface receptors that play a pivotal role in cell adhesion

and migration, as well as in growth and survival (1,2). The integrin family contains at least 18  $\alpha$  and 8  $\beta$  subunits that form 24 known integrins with distinct tissue distribution and overlaping ligand specificities (3). Integrins not only transmit signals to cells in response to the extracellular environment (outside-in signaling), but also sense intracellular cues to alter their interaction with extracellular environment (inside-out signaling) (1,2). Several  $\alpha V$  subfamily members, including  $\alpha V\beta 3$ ,  $\alpha V\beta 5$ ,  $\alpha V\beta 1$ , are highly expressed in active endothelial cells and cancer cells (3-6) where they play a critical role in angiogenesis and tumor metastasis (7-9). Therefore, interest has focused on  $\alpha V$  integrin as a key therapeutic target in the treatment of cancer (10-12).

Species: Rabbit Isotype: IgG

Storage/Stability: Store at -20oC or -80oC. Avoid freeze / thaw cycles. Buffer: PBS with 0.02% sodium azide,

50% glycerol, pH7.3.

**Synonyms:** CD51; MSK8; VNRA; VTNR;

Immunogen: A synthetic peptideof human ITGAV

**Purification:** Affinity purification

Reactivity: H M R
Applications: WB IHC
Molecular Weight: 115kDa
Swiss-Prot No.: P06756
Gene ID: 3685

References: 1. Liu, S. et al. (2000) J Cell Sci 113 ( Pt 20), 3563-71. 2. Hood, J.D. and Cheresh, D.A.

(2002) Nat Rev Cancer 2, 91-100. 3. Koistinen, P. et al. (2004) Int J Cancer 112, 61-70. 4. Davidson, B. et al. (2003) Gynecol Oncol 90, 248-57. 5. Schwartz, E.A. et al. (1999) Circ Res 84, 315-22. 6. Suzuma, K. et al. (1998) Invest Ophthalmol Vis Sci 39, 1028-35. 7. Eliceiri, B.P. and Cheresh, D.A. (1999) J Clin Invest 103, 1227-30. 8. Friedlander, M. et al. (1995) Science 270, 1500-2. 9. Perruzzi, C.A. et al. (2003) J Invest Dermatol 120, 1100-9. 10. Strieth, S. et al. (2006) Int J Cancer 119, 423-31. 11. Kumar, C.C. (2003) Curr Drug

Targets 4, 123-31. 12. Tucker, G.C. (2006) Curr Oncol Rep 8, 96-103.

